Navigation Links
King's College London reveals promising techniques for extending the life of an organ transplant
Date:9/15/2010

Experts from the Medical Research Council (MRC) Centre for Transplantation at King's College London, based at Guy's Hospital, have revealed exciting new scientific developments for people with an organ transplant, intended to help prevent rejection of the new organ and extend its life.

Although organ transplantation has been taking place for over 50 years, there are a number of significant challenges, such as a shortage of donor organs, maintaining the quality of an organ in transit, and the risk of organ rejection both immediately after transplant and in the following years.

Scientists at King's College London, part of King's Health Partners Academic Health Sciences Centre, are working hard to solve these problems through techniques known as protein therapeutics and cell therapy.

Protein therapeutics

The work using protein therapeutics aims to reduce the risk of an organ being damaged in the hours and days following a transplant, by maintaining the quality of the donor organ prior to transplantation.

Currently, organs cannot survive outside the body for more than around 24 hours. In daily life when an infection or virus meets cells or fluids in the body, it activates a part of the immune system, known as the 'complement' system, which attacks and attempts to destroy the cells of the intruder organism.

The complement system is usually kept in check by 'regulators' which are found on the surface of the cells. Their presence prevents it from attacking the body's own cells. However, when an organ is removed for transplantation, complement regulators are lost from the surface of cells due to the lack of blood flow and consequent lack of oxygen. Unregulated, the complement system begins to attack the organ's own cells, severely damaging it. Once the transplant is complete, the effect can be amplified as the complement system supports the recipient's own blood cells in its attack on the organ resulting in organ rejection.

Working with the biotechnology industry, scientists at the MRC Centre for Transplantation have evolved a method for coating the inner surface of donor kidneys with a protective layer made from a substance which is a natural regulator of these proteins in humans.

Dr Richard Smith, Director of Protein Therapeutics at the MRC Centre for Transplantation said: 'We have engineered a protein Mirococept to combat organ damage during transit outside the human body and immediately after transplantation. It is an artificial replacement for complement regulators. If enough Mirococept proteins reach the organ's cell membranes, it can prevent the complement cascade from starting and increases the number of donor organs suitable for transplantation.'

It is hoped this research will help alleviate the clear imbalance between supply and demand of donor organs for transplantation. According to NHS Blood and Transplant, at 31 March 2010, there were 7,183 patients waiting for a kidney transplant in the UK, and 2,694 kidney transplant operations were performed during the year 2009-10.

Dr Richard Smith and his team have also introduced the 'tail' in Mirococept which is specifically designed to latch on to cell walls. He continued: 'When we are preparing an organ for transplant we wash it in a solution, and the risk is that the protein will be washed off the organ. The 'tail' we have developed snags onto the cell surface and holds it there. Imagine the difference between throwing a bucket of water at a wall and throwing a bucket of paint, the water will run off but the paint will stick. This technique, known as tethering, not only enables the protein Mirococept to reach particular types of cells, but also gives it a much better chance of staying there.'

Mirococept has already been tested in a pilot scale clinical study of 16 kidney transplant patients and this showed that the tethering technique was clinically feasible and safe. The next step is large-scale clinical trials to test whether this method has clinical benefits for patients undergoing organ transplants.

Cell therapy

The other exciting area of research is cell therapy a type of potential treatment scientists hope will improve the longevity of a transplant.

Currently, transplant recipients have to stick to a strict regimen of potent drugs that pacify the immune system and hopefully prevent rejection of the donated organ. However, because these drugs suppress the immune system, they may also bring serious health complications, such as infections and some types of cancer.

Scientists at King's are looking at other ways of prolonging the life of a transplant, which involves using a type of white blood cell regulatory T cells found in healthy individuals as a treatment to prevent an individual's immune system from becoming over active and rejecting the organ.

Professor Giovanna Lombardi, Professor of Human Transplant Immunology at the MRC Centre for Transplantation, said: 'Animal studies have already shown that these cells can effectively prevent a transplant being rejected. We are currently identifying ways to 'grow' these cells from the blood of healthy individuals in the laboratory without them losing their ability to suppress other immune cells and are carrying out a study of the number and quality of regulatory T cells from patients on the waiting list for a kidney transplant. We are optimistic that we will be able to carry out the first clinical trials in transplant patients in the next few years.'

It is expected that any clinical trials would involve the isolation and expansion of these cells. The cells would be taken from a patient, multiplied in the laboratory into the numbers of cells needed, and reintroduced into the patients themselves. In any clinical trial, these cells would be generated in Good Manufacturing Practice (GMP) compliant facilities in development at Guy's Hospital.

The new research developments were presented at the British Science Festival in Birmingham.


'/>"/>

Contact: Melanie Haberstroh
melanie.haberstroh@kcl.ac.uk
44-020-784-83076
King's College London
Source:Eurekalert

Related medicine news :

1. Bluestar Silicones Launches a New Range of Silbione(R) TCS 7560 & 7561 Elastomers for Lingerie, Support Stockings and Medical Textile Applications
2. TFAH Praises New County Health Rankings Report
3. GSI Group Reports Preliminary Fourth Quarter 2009 Bookings, and Cash Balance
4. New Aspen Dental Office to Open in Kingston, New York
5. Jusuru Tops New Company Launch Rankings
6. St. Croix Systems Achieves Record First Half Bookings and Revenues in 2010, Driven by Demand for Innovative Patient Support Services Applications
7. Inner Workings of Gene Tied to Breast, Ovarian Cancer Revealed
8. College Age Females Can Kiss Chlamydia Goodbye for Valentines Day
9. Majority of Americans Approve of President Obamas Handling of Afghanistan and National Security But Disapprove of Handling of Economic Issues, Per Franklin & Marshall College Poll With Hearst Television
10. Parents Divorce Doesnt Harm College-Age Kids
11. Jefferson surgeon receives outstanding performance award from American College Of Surgeons
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... ... 26, 2017 , ... RawTrition now brings you BioEnergy which is a powder ... , RawTrition is taking nutrients to the next level! The superfoods ... its raw form (unlike the synthetically made options that are on the market). , ...
(Date:4/25/2017)... ... ... Bellus Medical, a leader in medical aesthetics, recently acquired ... photodynamic cosmetics (PDC). , Allumera® is the first PDC cream specifically formulated to ... minimize the appearance of pores – all with minimal downtime and results that ...
(Date:4/25/2017)... IN (PRWEB) , ... April 25, 2017 , ... ... D.C., CEOs, CFOs and HR decision-makers are preparing for how his administration could ... Financial will provide insight into what changes are most likely to make it ...
(Date:4/25/2017)... Switzerland (PRWEB) , ... April 25, 2017 , ... ... innovation targets, they rely on contracted partners to help with process innovation in ... of combined drug formulation experience along with state-of-the-art analytical equipment in support of ...
(Date:4/25/2017)... ... April 25, 2017 , ... Somnoware, a leading ... patient care management module. Using this new feature, sleep physicians can now predict ... on continuous positive airway pressure (CPAP), oral, or other forms of sleep apnea ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... , April 20, 2017 NeuroVive Pharmaceutical ... today announced positive preclinical results demonstrating anti-fibrotic ... for non-alcoholic steatohepatitis (NASH), in an additional ... NV556 has previously shown similar anti-fibrotic ... Today, NeuroVive,s scientists present novel data demonstrating ...
(Date:4/19/2017)... -- Cardiology devices segment is anticipated to reach the highest ... Devices segment is likely to create absolute $ opportunity of ... 2017. By the end of 2027, Cardiology Devices segment is ... Mn, expanding at a CAGR of 18.4% over the forecast ... Pacific reprocessed medical devices market in terms of ...
(Date:4/19/2017)... , April 19, 2017 Global Surgical Drainage ... are tubes used to remove excess liquid and air. ... pus, urine, bile or lymph. Surgical drains are used ... such as orthopedics surgery, cardiovascular surgery, neurosurgery, plastic surgery ... post-surgery to prevent accumulation of fluid e.g. blood or ...
Breaking Medicine Technology: